OCGN Historical PE Ratio Notes

— Ocugen, Inc. (OCGN) is a clinical-stage biopharmaceutical company focused primarily on developing gene therapies to treat rare eye diseases and, more recently, on vaccines and treatments related to infectious diseases. Its pipeline includes therapies for conditions such as retinitis pigmentosa & Leber congenital amaurosis, as well as COVID-19 vaccines through a partnership with Bharat Biotech. When you review historical PE ratio data for OCGN, it’s important to note that, as a pre-revenue or very low-revenue biotech, the company often reported little to no earnings over many periods, causing the traditional price-to-earnings (PE) ratio to either be extremely high, negative, or undefined. This is typical for early-stage biotech firms, where valuations are driven more by future growth potential & clinical milestones than by consistent profits. When examining historical charts, you may notice abrupt changes or gaps in the PE ratio that correspond to shifts in pipeline progress, regulatory news, or overall biotech market sentiment. Understanding that OCGN’s historical PE ratios don't generally reflect steady profitability, but rather expectations & speculation about future breakthroughs, is crucial for interpreting these figures as part of your research.

On this page we presented the Ocugen Historical PE Ratio information for Ocugen' stock. The average OCGN historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 55.6. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average OCGN historical PE based on this TTM earnings result method is 0.5. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this OCGN historical PE result, against the recent PE: when this page was posted on 10/5/2026, the most recent closing price for OCGN had been 1.04, and the most recent quarterly earnings result, annualized, was 0.08. Meanwhile, the most recent TTM earnings summed to 0.61. From these numbers, we calculate the recent OCGN PE on 10/5/2026 based on annualized quarterly EPS was 13.0. Based on OCGN's history, that recent PE is low relative to the historical average, with the recent PE 76.6% lower than the historical average PE across our data set for Ocugen. Looking at the recent OCGN PE on 10/5/2026 based on TTM EPS, we calculate the ratio at 1.7. Based on OCGN's history, that recent PE is elevated relative to the historical average, with the recent PE 240.0% higher than the historical average PE across our Ocugen data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on OCGN or any other given stock, valuation analysis for OCGN can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Ocugen PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for OCGN. Thanks for visiting, and the next time you need to research OCGN Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.